ARWR

SEC source: 0001628280-23-041966 · wk-form4_1703019238.xml · nonDerivative · entry 1

OLUKOTUN ADEOYE Y · CIK 0001242615 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,854

F1 · shares: Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary of the grant date.

SEC source: 0001628280-23-041963 · wk-form4_1703019121.xml · nonDerivative · entry 1

Vakiener Victoria · CIK 0001826263 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,721

F1 · acquired: Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary date.

SEC source: 0001628280-23-041962 · wk-form4_1703019085.xml · nonDerivative · entry 1

GIVEN DOUGLAS B · CIK 0001156207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,622

F1 · shares: Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary date.

SEC source: 0001628280-23-041960 · wk-form4_1703018485.xml · nonDerivative · entry 1

Waddill William D. · CIK 0001553338 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,804

F1 · shares: Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary date.

SEC source: 0001628280-23-039850 · wk-form4_1700681491.xml · nonDerivative · entry 2

San Martin Javier · CIK 0001794629 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 131,800

F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $28.91 to $29.15, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001628280-23-039850 · wk-form4_1700681491.xml · nonDerivative · entry 1

San Martin Javier · CIK 0001794629 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136,742

F1 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.90, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001628280-23-035430 · wk-form4_1698445412.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,737,000

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $23.97 to $24.74, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · acquired: Partial disposition of performance RSUs to satisfy tax withholding obligations. The performance RSUs were subject to a performance condition, which the Compensation Committee of the Company certified as achieved on October 22nd, 2023.

F4 · balance_after: 1,765,359 shares are subject to certain performance conditions that must be satisfied in order to vest.

SEC source: 0001628280-23-033520 · wk-form4_1696283491.xml · nonDerivative · entry 1

Vakiener Victoria · CIK 0001826263 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,734

F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001628280-23-032707 · wf-form4_169524780099268.xml · derivative · entry 4

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 409,225

Underlying: Common Stock · 57,555 shares

Expires 2023-09-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Represents first vesting date. Option vested over four years from the first vesting date.

F5 · balance_after: Represents total stock options beneficially owned at various strike prices

SEC source: 0001628280-23-032707 · wf-form4_169524780099268.xml · nonDerivative · entry 3

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,761,338

F1 · kind: The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.14 to $28.94, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001628280-23-032707 · wf-form4_169524780099268.xml · nonDerivative · entry 2

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,787,570

F1 · kind: The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.54 to $28.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001628280-23-032707 · wf-form4_169524780099268.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,819,093

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001628280-23-024494 · wk-form4_1688681055.xml · nonDerivative · entry 1

Oliver Tracie · CIK 0001935706 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,575

F1 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $34.95 to $35.94, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001628280-23-024351 · wk-form4_1688595303.xml · nonDerivative · entry 1

Hamilton James C · CIK 0001830755 · Chief Discovery/Trans Medicine

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,484

F1 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $35.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001628280-23-023950 · wf-form4_168807847193372.xml · nonDerivative · entry 1

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 381,704

F1 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $36.08 to $36.26, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001628280-23-016560 · wf-form4_168358492995664.xml · nonDerivative · entry 1

GIVEN DOUGLAS B · CIK 0001156207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,635

F1 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $40.59 to $41.22, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the reporting person which are subject to certain vesting conditions.

SEC source: 0001628280-23-016223 · wf-form4_168332785863869.xml · derivative · entry 7

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 466,980

Underlying: Common Stock · 50,000 shares

Expires 2023-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant.

F6 · balance_after: Represents total stock options beneficially owned at various strike prices.

SEC source: 0001628280-23-016223 · wf-form4_168332785863869.xml · nonDerivative · entry 5

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,761,338

F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.48 to $40.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001628280-23-016223 · wf-form4_168332785863869.xml · nonDerivative · entry 4

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,787,330

F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.47 to $39.47, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001628280-23-016223 · wf-form4_168332785863869.xml · nonDerivative · entry 3

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,811,338

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · acquired: Acquired through exercise of options expiring 5/6/23. See Table II.

SEC source: 0001628280-23-016223 · wf-form4_168332785863869.xml · derivative · entry 6

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 516,980

Underlying: Common Stock · 54,928 shares

Expires 2023-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant.

F6 · balance_after: Represents total stock options beneficially owned at various strike prices.

SEC source: 0001628280-23-016223 · wf-form4_168332785863869.xml · nonDerivative · entry 2

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,761,338

F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.84 to $39.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001628280-23-016223 · wf-form4_168332785863869.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,816,266

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · acquired: Acquired through exercise of options expiring 5/6/23. See Table II.

SEC source: 0001209191-23-016446 · doc4.xml · nonDerivative · entry 1

OLUKOTUN ADEOYE Y · CIK 0001242615 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,867

F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.36 to $32.88, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-23-014275 · doc4.xml · nonDerivative · entry 1

GIVEN DOUGLAS B · CIK 0001156207 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 13,000

F1 · ownership.nature: Represents securities owned directly by Anne Given Trust ("AG Trust"). Mr. Given, as co-trustee of AG Trust, may be deemed to beneficially own the securities owned directly by AG Trust.

SEC source: 0001209191-23-003081 · doc4.xml · derivative · entry 2

De Backer Marianne · CIK 0001797819 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,593

Underlying: Common Stock · 4,593 shares

Expires 2033-01-10

F2 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003081 · doc4.xml · nonDerivative · entry 1

De Backer Marianne · CIK 0001797819 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,267

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003079 · doc4.xml · derivative · entry 3

Vakiener Victoria · CIK 0001826263 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,593

Underlying: Common Stock · 4,593 shares

Expires 2033-01-10

F4 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003079 · doc4.xml · nonDerivative · entry 2

Vakiener Victoria · CIK 0001826263 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,284

F2 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

F3 · balance_after: Includes a total of 15,417 shares underlying restricted stock units, which vest over three years.

SEC source: 0001209191-23-003079 · doc4.xml · nonDerivative · entry 1

Vakiener Victoria · CIK 0001826263 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,417

F1 · shares: Correction to previously granted award from 17,181 to 15,417.

SEC source: 0001209191-23-003077 · doc4.xml · derivative · entry 2

PERRY MICHAEL S · CIK 0001250379 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,593

Underlying: Common Stock · 4,593 shares

Expires 2033-01-10

F2 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003077 · doc4.xml · nonDerivative · entry 1

PERRY MICHAEL S · CIK 0001250379 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,767

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003075 · doc4.xml · derivative · entry 2

GIVEN DOUGLAS B · CIK 0001156207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,593

Underlying: Common Stock · 4,593 shares

Expires 2033-01-10

F2 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003075 · doc4.xml · nonDerivative · entry 1

GIVEN DOUGLAS B · CIK 0001156207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,135

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003073 · doc4.xml · derivative · entry 3

Waddill William D. · CIK 0001553338 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,593

Underlying: Common Stock · 4,593 shares

Expires 2033-01-10

F3 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003073 · doc4.xml · nonDerivative · entry 2

Waddill William D. · CIK 0001553338 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,817

F2 · shares: Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003071 · doc4.xml · derivative · entry 2

OLUKOTUN ADEOYE Y · CIK 0001242615 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,593

Underlying: Common Stock · 4,593 shares

Expires 2033-01-10

F2 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003071 · doc4.xml · nonDerivative · entry 1

OLUKOTUN ADEOYE Y · CIK 0001242615 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,217

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003108 · doc4.xml · derivative · entry 2

Ferrari Mauro · CIK 0001506045 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,593

Underlying: Common Stock · 4,593 shares

Expires 2033-01-10

F2 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003108 · doc4.xml · nonDerivative · entry 1

Ferrari Mauro · CIK 0001506045 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,838

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-23-003073 · doc4.xml · nonDerivative · entry 1

Waddill William D. · CIK 0001553338 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,950

F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001209191-23-002481 · doc4.xml · nonDerivative · entry 2

O'Brien Patrick · CIK 0001627183 · COO and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 413,375

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.90 to $37.73, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-23-002481 · doc4.xml · nonDerivative · entry 1

O'Brien Patrick · CIK 0001627183 · COO and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 420,875

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.85 to $37.73, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002479 · doc4.xml · nonDerivative · entry 2

Hamilton James C · CIK 0001830755 · Chief Discovery/Trans Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,484

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.88 to $37.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-23-002479 · doc4.xml · nonDerivative · entry 1

Hamilton James C · CIK 0001830755 · Chief Discovery/Trans Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 198,057

F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.89 to $37.64, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-23-002121 · doc4.xml · nonDerivative · entry 1

Oliver Tracie · CIK 0001935706 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,500

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments, with a commencement date of 1/4/23.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-23-002119 · doc4.xml · nonDerivative · entry 1

San Martin Javier · CIK 0001794629 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,500

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments, with a commencement date of 1/4/23.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-23-002116 · doc4.xml · nonDerivative · entry 1

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 396,704

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments, with a commencement date of 1/4/23.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 9

O'Brien Patrick · CIK 0001627183 · COO and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 428,375

F9 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments, with a commencement date of 1/4/23.

F10 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

SEC source: 0001209191-23-002110 · doc4.xml · nonDerivative · entry 9

Hamilton James C · CIK 0001830755 · Chief Discovery/Trans Medicine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,287

F10 · shares: Represents shares underlying restricted stock units, which will vest in four equal installments, with a commencement date of 1/4/23.

F11 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.